ImmunID Announces Incorporation and US Development Plans
GRENOBLE, France, March 16, 2016 /PRNewswire/ -- ImmunID, the immune companion diagnostics for precision medicine company, today announces the incorporation of a US subsidiary, ImmunID Inc. The new company will support the development of ImmunID's activities in the United States and the access of ImmunTraCkeR® to American patients.
Dr. Bernhard Sixt, Chairman and Chief Executive Officer of ImmunID, commented: "For over a year, ImmunID has been processing clinical patient samples from our PredictID program in France. Just recently we have deployed our activities to the United Kingdom. Our expansion to the United States, the largest market for immuno-oncology, is the next logical step and will extend our commercial footprint in North America."
ImmunID adds precision to the immuno-oncology revolution by personalizing immunotherapy for cancer patients. With its decade-long experience in immune molecular diagnostics, ImmunID provide doctors with clinically meaningful data on the highly complex immune system to select the right therapy for individual patients and to monitor their response. ImmunID's flagship CE-marked product, ImmunTraCkeR®, evaluates the patient's immune status based on the T lymphocyte diversity, from a simple liquid biopsy. The company is establishing ImmunTraCkeR® as the general immune companion diagnostic assay for immune checkpoint inhibitors and other immunotherapies. In addition, ImmunID collaborates with pharma and biotech companies to optimize the development of their next-generation immunotherapies. ImmunID is ISO 9001 and ISO 13485 certified and runs a CAP-accredited laboratory in the MINATEC high-tech campus in Grenoble, France.
ImmunTraCkeR® is a proprietary CE-marked immune molecular diagnostics assay, which evaluates a patient's immune status in the blood based on combinatorial T cell diversity. Unlike most companion diagnostics tests, ImmunTraCkeR® is patient-specific rather than drug- or disease-specific, as it approaches the disease from the patient's own immune system perspective. ImmunTraCkeR® provides information on the patient's complex immune profile to evaluate clinical benefit or risk under treatment with immunotherapies. ImmunTraCkeR® may ultimately be used as immune companion diagnostics and answer the urgent medical need for efficient patient stratification tools in melanoma and other solid cancers.
Dr. Bernhard Sixt
Chairman and CEO
Phone: +33 438 785 770
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immunid-announces-incorporation-and-us-development-plans-300236906.html